February 5, 2018 09:41 AM EST
News Briefing

Al­ler­gan taps Catal­en­t's Matthew Walsh as CFO; Re­Vi­ral meets end­points in PhI­Ia RSV tri­al

Amber Tong

→ Af­ter a months-long hunt, Al­ler­gan $AGN has locked in Matthew Walsh as the suc­ces­sor of out­go­ing CFO Maria Tere­sa Hi­la­do, who an­nounced the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times